Literature DB >> 11500396

vsp gene expression by Giardia lamblia clone GS/M-83-H7 during antigenic variation in vivo and in vitro.

M Bienz1, M Siles-Lucas, P Wittwer, N Müller.   

Abstract

Giardia lamblia infections are associated with antigenic variation of the parasite, which is generated by a continuous change of the variant-specific surface proteins (VSPs). Many investigations on the process of antigenic variation were based on the use of G. lamblia clone GS/M-83-H7, which expresses VSP H7 as its major surface antigen. In the present study, mice were infected with the aforementioned clonal line to investigate vsp gene expression during the complex process of antigenic variation of the parasite. Trophozoites collected from the intestines of individual animals at different time points postinfection (p.i.) were analyzed directly for their vsp gene expression patterns, i.e., without cultivating the recovered parasites in vitro. Because few trophozoites were recovered at late time points p.i., a combined 5' rapid amplification of cDNA ends-reverse transcription-PCR approach was utilized. This allowed detection and subsequent sequence analysis of vsp gene transcripts upon generation of amplified cDNA analogues. The same PCR approach was applied for analysis of vsp gene expression in variants obtained after negative selection of axenic GS/M-83-H7 trophozoites by treatment with a cytotoxic, VSP H7-specific monoclonal antibody. In an overall view of the entire panel of in vivo- and in vitro-derived parasite populations, expression of 29 different vsp gene sequences could be demonstrated. In vivo antigenic variation of G. lamblia clone GS/M-83-H7 was shown to be a continuous process involving the consecutive appearance of relatively distinct sets of vsp transcripts. During the 42-day infection period investigated, this process activated at least 22 different vsp genes. Comparative molecular analyses of the amino acid level demonstrated that all cDNA segments identified encode structural elements typical of the terminal segment of Giardia VSP. The similarity of most of the GS/M-83-H7 VSP sequences identified in the present study supports previous suggestions that vsp gene diversification in G. lamblia is the result of ancestral gene duplication, mutation, and/or recombination events.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500396      PMCID: PMC98636          DOI: 10.1128/IAI.69.9.5278-5285.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Characterization of a Giardia lamblia variant-specific surface protein (VSP) gene from isolate GS/M and estimation of the VSP gene repertoire size.

Authors:  T E Nash; M R Mowatt
Journal:  Mol Biochem Parasitol       Date:  1992-04       Impact factor: 1.759

2.  Electron microscopical investigation of surface alterations on Giardia lamblia trophozoites after exposure to a cytotoxic monoclonal antibody.

Authors:  A Hemphill; S Stäger; B Gottstein; N Müller
Journal:  Parasitol Res       Date:  1996       Impact factor: 2.289

3.  Antigenic variation in Giardia lamblia.

Authors:  T E Nash; A Aggarwal; R D Adam; J T Conrad; J W Merritt
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

4.  Cross-reactivity among different Giardia lamblia isolates using immunofluorescent antibody and enzyme immunoassay techniques.

Authors:  B L Ungar; T E Nash
Journal:  Am J Trop Med Hyg       Date:  1987-09       Impact factor: 2.345

Review 5.  Antigenic variation in Giardia lamblia and the host's immune response.

Authors:  T E Nash
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

6.  Antigenic variation in Giardia lamblia: cellular and humoral immune response in a mouse model.

Authors:  B Gottstein; G R Harriman; J T Conrad; T E Nash
Journal:  Parasite Immunol       Date:  1990-11       Impact factor: 2.280

7.  Differentiation-associated surface antigen variation in the ancient eukaryote Giardia lamblia.

Authors:  S G Svärd; T C Meng; M L Hetsko; J M McCaffery; F D Gillin
Journal:  Mol Microbiol       Date:  1998-12       Impact factor: 3.501

8.  Variant surface antigens of Giardia lamblia are associated with the presence of a thick cell coat: thin section and label fracture immunocytochemistry survey.

Authors:  P F Pimenta; P P da Silva; T Nash
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum.

Authors:  D R Hill; J J Burge; R D Pearson
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

10.  Carboxy-terminal sequence conservation among variant-specific surface proteins of Giardia lamblia.

Authors:  M R Mowatt; A Aggarwal; T E Nash
Journal:  Mol Biochem Parasitol       Date:  1991-12       Impact factor: 1.759

View more
  13 in total

1.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

2.  Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvum antigens.

Authors:  Jeffrey W Priest; Delynn M Moss; Govinda S Visvesvara; Cara C Jones; Anna Li; Judith L Isaac-Renton
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

3.  Identification of variant-specific surface proteins in Giardia muris trophozoites.

Authors:  Andrea S Ropolo; Alicia Saura; Pedro G Carranza; Hugo D Lujan
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Central importance of immunoglobulin A in host defense against Giardia spp.

Authors:  T Dianne Langford; Michael P Housley; Marianne Boes; Jianzhu Chen; Martin F Kagnoff; Frances D Gillin; Lars Eckmann
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Use of Serologic Responses against Enteropathogens to Assess the Impact of a Point-of-Use Water Filter: A Randomized Controlled Trial in Western Province, Rwanda.

Authors:  Laura Divens Zambrano; Jeffrey W Priest; Emil Ivan; John Rusine; Corey Nagel; Miles Kirby; Ghislaine Rosa; Thomas F Clasen
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

6.  Interleukin-6-deficient mice are highly susceptible to Giardia lamblia infection but exhibit normal intestinal immunoglobulin A responses against the parasite.

Authors:  Marianne Bienz; Wen Juan Dai; Monika Welle; Bruno Gottstein; Norbert Müller
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

7.  Experimental infections of neonatal mice with cysts of Giardia lamblia clone GS/M-83-H7 are associated with an antigenic reset of the parasite.

Authors:  N von Allmen; M Bienz; A Hemphill; N Müller
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Seroprevalence of antibodies against Chlamydia trachomatis and enteropathogens and distance to the nearest water source among young children in the Amhara Region of Ethiopia.

Authors:  Kristen Aiemjoy; Solomon Aragie; Dionna M Wittberg; Zerihun Tadesse; E Kelly Callahan; Sarah Gwyn; Diana Martin; Jeremy D Keenan; Benjamin F Arnold
Journal:  PLoS Negl Trop Dis       Date:  2020-09-02

9.  The Giardia lamblia vsp gene repertoire: characteristics, genomic organization, and evolution.

Authors:  Rodney D Adam; Anuranjini Nigam; Vishwas Seshadri; Craig A Martens; Gregory A Farneth; Hilary G Morrison; Theodore E Nash; Stephen F Porcella; Rima Patel
Journal:  BMC Genomics       Date:  2010-07-09       Impact factor: 3.969

10.  Draft genome sequencing of giardia intestinalis assemblage B isolate GS: is human giardiasis caused by two different species?

Authors:  Oscar Franzén; Jon Jerlström-Hultqvist; Elsie Castro; Ellen Sherwood; Johan Ankarklev; David S Reiner; Daniel Palm; Jan O Andersson; Björn Andersson; Staffan G Svärd
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.